Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 255 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Dear Prime Minister: “Please don’t delay action again, we’re counting on... October 16, 2020 7 Practical Tips for Taking Long-Term Medication January 9, 2024 News digest – cancer blood test, gum disease and junk food... July 25, 2020 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Load more HOT NEWS FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma The Pesticide Chemical Responsible For Mass Bee Die-Offs Is Killing Birds... Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for... Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:...
